Learn about a clinical trial for AML

Because every moment matters.

If you have been newly diagnosed with acute myeloid leukemia (AML), the QuANTUM-First Study may be an option for you. The study is evaluating an investigational medication for AML, given in addition to chemotherapy.

For more information call <span><a class="phone-call" href="tel:+18885757573">1-888-575-7573</a> or</span> See If You Qualify

About the Study

What is the ASCENT Study?

The ASCENT Study is a clinical research study evaluating a medication for patients diagnosed with COPD, who also have a history of heart disease, stroke or other cardiovascular risk factors.

The purpose of this study is to determine how the medication manages and controls COPD symptoms, as well as how it affects the patient’s cardiovascular safety.

Treatment Sequence


(up to 2 cycles)

GOAL: Reduce cancer cells


(up to 4 cycles of chemotherapy, transplant allowed)

GOAL: Further reduce cancer cells


(up to 12 cycles)

GOAL: Maintain remission and prevent relapse

Participating in the QuANTUM-First Study will not interfere with your ability to receive a stem cell transplant.

For more information call <span><a class="phone-call" href="tel:+18885757573">1-888-575-7573</a> or</span> See If You Qualify

Do I Qualify?

I have AML. Am I eligible for the QuANTUM-First Study?

You may qualify to participate in the study if:
  • You are between 18-75 years of age
  • You have been diagnosed with AML, and
  • Your test results come back positive for the FLT3-ITD genetic mutation
    • It’s likely that you’ll find this out during the first few days of your initial chemotherapy treatment (also known as induction chemotherapy)

Talk to your doctor and loved ones if you are interested in the QuANTUM-First Study. Your doctor can give you more information about the clinical trial and help you decide if it’s right for you.

Participating in the QuANTUM-First Study will not delay the start of your chemotherapy treatment.

For more information call <span><a class="phone-call" href="tel:+18885757573">1-888-575-7573</a> or</span> See If You Qualify

About AML & FLT3-ITD

What is AML with FLT3-ITD?

Acute myeloid leukemia (AML) is a type of cancer that begins in the bone marrow and moves into the bloodstream.

AML is usually fast growing and needs to be treated quickly. Your doctor may have already performed blood and bone marrow tests to determine the type of AML you have, as well as any changes or mutations in your genes.

In some people, having a genetic mutation known as FLT3-ITD makes the disease more difficult to treat and relapse more likely. However, new drugs that target the FLT3-ITD mutation are currently being developed through clinical trials.

The National Comprehensive Cancer Network (NCCN) recommends that you speak with your physician to see if a clinical trial may be right for you.1

For additional information about clinical trials, please see http://www.cancer.gov/about-cancer/treatment/clinical-trials

  • Reference: 1. Panel chair, et. al., NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Myeloid Leukemia Version 1.2015. © 2014 National Comprehensive Cancer Network, Inc. Available at NCCN.org. Accessed February 4, 2016.
For more information call <span><a class="phone-call" href="tel:+18885757573">1-888-575-7573</a> or</span> See If You Qualify


FAQs about the ASCENT Study

  • What is the purpose of the ASCENT Study?

    The purpose of the study is to determine how the medication manages and controls COPD symptoms as well as how it affects the patient's cardiovascular safety.

  • Who is conducting the ASCENT Study?

    The ASCENT Study is being conducted by trained, qualified, licensed physicians and medical specialists.

  • Will I have to pay for anything if I participate in the ASCENT Study?

    If you qualify for the ASCENT Study, study-related medical exams and the study-related medication will be provided to you at no cost.

  • How many people will participate in the ASCENT Study?

    About 4,000 people are expected to participate in the ASCENT Study.

  • How long does the ASCENT Study last?

    Your participation in the ASCENT Study may last up to 36 months and you will visit the study office up to 12 times during this period of time.

  • What are the risks of participating in the ASCENT Study?

    You could experience side effects associated with the study-related medication(s). The study staff will discuss all of the possible risks and potential benefits with you in detail before you decide to participate.

  • What is a placebo and could I receive one in the ASCENT Study?

    A placebo is used in clinical trials to determine if the active medication being evaluated is more effective and safer than no treatment at all. In this study, the placebo is a dry powder taken via inhaler; the placebo contains no active medication. There is a 50% chance that you will receive placebo during the ASCENT Study. You will also be given rescue medication (albuterol) - a drug that opens up your airways to provide fast relief of COPD symptoms like shortness of breath and wheezing. The FDA has approved albuterol to treat symptoms in people with COPD.

  • What happens after the ASCENT Study is complete?

    After the ASCENT Study is complete, all of the information is analyzed to help determine the study-related medication’s effectiveness and safety.

  • Does my primary care physician have to give his or her permission for me to participate in the ASCENT Study?

    No. However, it is a good idea to let your doctor know that you plan to participate in the ASCENT Study. With your permission, your doctor can contact the study doctor for more information at any time.

    The study doctor will not take the place of your usual doctor. You should continue to see your regular doctor for any non-study-related medical care.

  • Who is sponsoring the ASCENT Study?

    AstraZeneca is sponsoring the ASCENT Study.

FAQs about clinical research

  • What is a clinical research study?

    A clinical research study is carefully supervised research done to evaluate medications in development or currently approved. Clinical research studies are performed according to government regulations, which help protect the safety and rights of study participants. The goal of clinical research is to answer specific health questions, evaluate the effectiveness and safety of medications and discover new ways to improve health.

  • Is participation in a clinical research study voluntary?

    Yes, participation in any clinical research study is completely voluntary. If you decide to participate in a clinical research study, you are always free to withdraw at any time for any reason without any penalty or effect on your future medical care.

  • What is informed consent?

    Informed consent is the process of learning the key facts and details about a clinical research study. This information will be provided to you before you decide to participate, as well as during your continued participation throughout the study. Once you have read the informed consent and understand the details including the benefits and risks, you can decide whether or not to sign the document. No study-related procedures will take place without a signed informed consent form.

  • What happens to my personal information?

    Information about your personal health is private and confidential. With your permission, the information you provide about your medical history and health condition can be transferred to the study physician's office of your choice.

    If you qualify for the study, a representative from the study physician’s office will contact you to further determine your interest and eligibility. Your personal information will not be disclosed to anyone outside of this clinical research study group without your consent unless disclosure is required by law or regulations of the FDA or similar agencies in other countries.

    Scientific presentations of study results will not include information that could in any way identify you.

  • What happens to my personal information?

    Your personal information will not be shared with anyone who is not directly associated with this research program without your permission (except as required by law).

  • Who oversees clinical trials?

    To help ensure that a clinical trial is ethical and that volunteers’ rights are protected, Institutional Review Boards (IRB) or Ethics Committees (EC) review and approve study protocols.

  • Who can participate in a clinical trial?

    You must meet all of the study eligibility criteria in order to take part. To see if you qualify, the study team will review your medical history and evaluate your current medical status.

Contact a QuANTUM-First Study Site

For more information or to see if you may qualify for the QuANTUM-First Study, please contact a study site.

Study sites currently enrolling patients


ajax loader